Results 61 to 70 of about 17,566 (194)

What's Your Diagnosis? A Case of Extreme Thrombocytosis in a Dog

Veterinary Clinical Pathology, EarlyView.
Stephanie F. Anderson, King Long Hannah Lee, Megan Dietz, Sarah Guess, Laura White, Mara S. Varvil   +5 more
wiley   +1 more source

Epigenomic profiling of myelofibrosis reveals widespread DNA methylation changes in enhancer elements and ZFP36L1 as a potential tumor suppressor gene that is epigenetically regulated

Haematologica, 2019
In this study we interrogated the DNA methylome of myelofibrosis patients using high-density DNA methylation arrays. We detected 35,215 differentially methylated CpG, corresponding to 10,253 genes, between myelofibrosis patients and healthy controls ...
Nicolás Martínez-Calle, Marien Pascual, Raquel Ordoñez, Edurne San José Enériz, Marta Kulis, Estíbaliz Miranda, Elisabeth Guruceaga, Víctor Segura, María José Larráyoz, Beatriz Bellosillo, María José Calasanz, Carles Besses, José Rifón, José I. Martín-Subero, Xabier Agirre, Felipe Prosper   +15 more
doaj   +1 more source

This Is Not a Myeloproliferative Neoplasm…

Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
Stephanie Juané Kennedy
wiley   +1 more source

Genetic Variants of BMI1 (rs1042059 and rs11591377) and Their Potential Role in Leukemia Susceptibility: A Narrative Review

Health Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background and Aims Leukemia is a heterogeneous group of hematologic malignancies influenced by both genetic and environmental factors. The B‐cell‐specific Moloney murine leukemia virus integration site 1 (BMI1) gene, a key regulator of hematopoietic stem cell self‐renewal and oncogenesis, has been implicated in leukemia pathogenesis.
Mojtaba Aghaei, Niloufar Afrough, Mohammad Ali Jalali Far   +2 more
wiley   +1 more source

A Systematic Review of Literature: TNF‐α Blockers and JAK Inhibitors for the Treatment of Stevens‐Johnson Syndrome, Toxic Epidermal Necrolysis, and Severe Forms of Erythema Multiforme

Health Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background and Aims Stevens‐Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme major (EM major) are severe dermatologic conditions characterized by varying degrees of skin detachment and involvement of mucosal membranes, often triggered by drug reactions or infections.
Sadaf Salehi, Pooneh Torabi, Mahsa Abbaspour, Nima Hajizadeh, Sara Sadeghi, Alireza Jafarzadeh, Azadeh Goodarzi   +6 more
wiley   +1 more source

Calreticulin Type 26 Mutation in Myelofibrosis: A Rare Variant With Diagnostic Challenges

Journal of Clinical Laboratory Analysis, Volume 40, Issue 11, June 2026.
ABSTRACT Background Myeloproliferative neoplasms (MPNs) are clonal hematologic disorders commonly driven by mutations in JAK2, MPL, or CALR. Because routine CALR assays are largely optimized for the canonical Type 1 and Type 2 exon 9 variants, rare noncanonical mutations may be missed, creating diagnostic challenges.
Teresa Maltese, Giuseppina Raffa, Fabio Stagno, Rossana Leanza, Paola Barone, Alessandro Allegra, Teresa Pollicino   +6 more
wiley   +1 more source

Childhood primary myelofibrosis presented with headache, splenomegaly, and severe thrombocytosis: A case report

Indian Journal of Medical and Paediatric Oncology, 2018
Primary myelofibrosis (PMF) is a clonal disorder of a multipotent hematopoietic progenitor cell that occurs predominantly in the elderly age group. We report here an 11-year-old girl who presented with headache, fever, and splenomegaly.
Athanasios Tragiannidis, Athanasia Apsemidou, Ioannis Liampas, Triantafyllia Koletsa   +3 more
doaj   +1 more source

Development of Dermatomyositis in a Patient with Primary Myelofibrosis

Hematology, 2001
It is known that immunologic mechanisms play an important role in the disease process of some patients with idiopathic myelofibrosis. Patients with idiopathic myelofibrosis have an increased incidence of autoantibodies and circulating immune complexes.
TAŞKAPAN, HÜLYA, Gürsoy, S., Oymak, O., ÇETİN, MEHMET YAVUZ, Özbakir, Ö.   +4 more
openaire   +3 more sources

Single‐Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis: Results From the Phase 2 XPORT‐035 Study

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Background Janus kinase inhibitors (JAKis), the current standard of care for myelofibrosis (MF), provide clinical benefit, but responses are frequently incomplete, non‐durable, and associated with cytopenias, underscoring the need for therapies with novel mechanisms of action.
Sebastian Grosicki, Habte Yimer, Rosa Ayala, Suning Chen, Hong Liu, Françoise Boyer, Paola Guglielmelli, Marco Brociner, Paolo Sportoletti, Gabor Mikala, Panagiotis Tsirigotis, Jin Zhang, Tomer Mark, Yi Chai, Andrea Ellero, Alessandro Lucchesi   +15 more
wiley   +1 more source

Involvement of TGFβ1 in autocrine regulation of proplatelet formation in healthy subjects and patients with primary myelofibrosis

Haematologica, 2013
Megakaryocytes release platelets into the bloodstream by elongating proplatelets. In this study, we showed that human megakaryocytes constitutively release Transforming Growth Factor β1 and express its receptors.
Stefania Badalucco, Christian Andrea Di Buduo, Rita Campanelli, Isabella Pallotta, Paolo Catarsi, Vittorio Rosti, David L. Kaplan, Giovanni Barosi, Margherita Massa, Alessandra Balduini   +9 more
doaj   +1 more source